Navigation Links
PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
Date:4/23/2008

, producing a shortened, non- functional protein. PTC124 has restored production of full-length, functional proteins in preclinical genetic disease models harboring nonsense mutations. In Phase 1 clinical trials, PTC124 was generally well tolerated, achieved target plasma concentrations that have been associated with activity in preclinical models and did not induce ribosomal read through of normal stop codons. PTC124 has demonstrated pharmacodynamic proof of concept in Phase 2a clinical trials in nonsense-mutation-mediated Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF).

It is estimated that 13% of the cases of DMD and 10% of the cases of CF are due to nonsense mutations. PTC believes that PTC124 is potentially applicable to a broad range of other genetic disorders in which a nonsense mutation is the cause of the disease. The FDA has granted PTC124 Subpart E designation for expedited development, evaluation, and marketing and has granted Orphan Drug designations for the treatment of CF and DMD due to nonsense mutations. PTC124 has also been granted orphan drug status for the treatment of CF and DMD by the European Commission. PTC124's development has been supported by grants from the Muscular Dystrophy Association (MDA), Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), Parent Project Muscular Dystrophy (PPMD), FDA's Office of Orphan Products Development (OOPD) and by General Clinical Research Center grants from the National Center for Research Resources (NCRR). For additional information on the PTC124 clinical trial, please visit http://www.clinicaltrials.gov and search using the keyword: PTC124.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulat
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
2. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
3. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
5. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
6. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
7. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
8. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
9. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014  Strategic Health Services, Inc. (SHS), a leading ... a strategic agreement with QualCare, Inc., a leading provider of ... regional marketplace.  This agreement will further QualCare,s population ... solutions QualCare brings to its clients in ... QualCare plans cover more than 800,000 member ...
(Date:12/17/2014)... ANGELES , Dec. 17, 2014  ImmunoCellular ... the US Patent and Trademark Office (USPTO) has ... ICT-107, a dendritic cell-based immunotherapeutic vaccine targeting six ... The claims of US Patent No. 8,871,211, which ... neural cancer by administering a dendritic cell composition ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind ... Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ ... zu besuchen. Diese Tagung soll ... die Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, ...
Breaking Medicine Technology:Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... May 24 Perrigo Company (Nasdaq: PRGO ; TASE) ... will present at the Citi Investment Research Global Health Care Conference on ... the New York Hilton.  The presentation will be webcast on the following ... , , ...
... , MOSCOW , May 24 The international forum "Drug ... held in Moscow on June 9 and 10, 2010, ... , Heads ... gather in Moscow for a conference initiated by the Russian News ...
Cached Medicine Technology:Drug Production in Afghanistan: A Challenge for the International Community 2
(Date:12/17/2014)... Alan Mozes HealthDay Reporter ... holiday party season fast approaching, a new study reveals that ... arrests have fewer drunk drivers on their roads. The ... vigilantly are better able to deter inebriated revelers from getting ... new laws are being passed regarding drinking and driving," said ...
(Date:12/15/2014)... 15, 2014 Veretekk.com, Inc. announced today ... Avenue. JM Ocean Avenue has secured exclusive benefit ... automated marketing system. JM Ocean Avenue is a ... of Ocean Avenue and JM International, with partial ownership ... per year company. , “After nearly 2 decades of ...
(Date:12/15/2014)... December 15, 2014 Health Dialog, ... announced today that it has received Patient Oriented ... (NCQA) for its Disease Management (DM) Programs for ... (COPD), coronary heart disease and diabetes. This marks ... for Health Dialog’s Disease Management (DM) Programs, reaffirming ...
(Date:12/15/2014)... 15, 2014 Emergo Group, Inc., a ... countries in North and South America, Europe, the Middle ... industry participants for its 2015 Medical Device Industry Survey. ... identify upcoming business and market trends as well as ... survey targets areas including:, , Overall ...
(Date:12/15/2014)... 15, 2014 For the second year in ... “Top 30 Coffees of 2014.” Bird Rock Coffee Roasters’ Sumatra ... Zone Ethiopia at number 10. This is the first year ... Review’s selection is ranked on quality, value, and other aspects, ... 96 out of 100, and at $17.99 for 12-ounces, was ...
Breaking Medicine News(10 mins):Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 2Health News:Enforcement of Drunk Driving Laws Makes Roads Safer, Study Finds 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:Bird Rock Coffee Roasters Ranks Second and Tenth in Coffee Review’s ‘Top 30 Coffees of 2014’ 2
... Duke University Medical Center say they may have figured ... health in women than in men. , Their study, ... found that poor sleep is associated with greater psychological ... risk of heart disease and type 2 diabetes. ...
... First Dual-Source CT System Brings More Innovative Diagnostics to the ... ... MALVERN, Pa., March 10 Encouraged by the outstanding,marketing success of ... Healthcare, (http://www.siemens.com/healthcare ) announces the 510(k) market clearance of four,new applications ...
... reality therapy for stroke patients. One commonly used program ... screen. For example, tennis balls are virtually thrown at ... hand motions are recorded on screen. In the first ... Dr. Larry Manevitz of the University of Haifa, together ...
... 10 MS Awareness Week March,10 - 17 unites ... of,multiple sclerosis nationwide in an effort to shine a ... MS, a disease where someone is,newly diagnosed each hour., ... you Do?, Ways To Join The MS Movement, ...
... -- Research published in the March issue of ... Psychological Science, is suggesting that we process images ... of the Negev Psychologist Tzvi Ganel and his ... an image common in psychological research that makes ...
... Oxfordshire, March 10 IBA,Health Group company iSOFT ... become its first healthcare channel partner in Europe ... provisioning solutions., The move coincides with the ... iSOFT to become the first partner to offer ...
Cached Medicine News:Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 2Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 3Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 4Health News:Virtual reality and computer technology improve stroke rehabilitation 2Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 2Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 3Health News:What Will You Do? Join the Movement to End Multiple Sclerosis During MS Awareness Week March 10-17 4Health News:The hand can't be fooled, study shows 2Health News:iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion 2Health News:iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion 3Health News:iSOFT Offers Healthcare Single Sign-On Solutions After Agreement with Sentillion 4
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The proprietary ... reagent provides a long shelf life ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
LCD chart display...
Mobile offers full life cycle service for Sp02 accessories that are the vital link between pulse oximeter and patient...
Medicine Products: